The Latest Breaking News from Morgan Stanley

3 Top Stocks Set to Surge as Morgan Stanley Eyes Dollar Weakness

As Morgan Stanley analysts say to sell the dollar, a few stocks might outperform if their view is right. Domestic manufacturing and overseas stocks agree

MarketBeat · Dec 12, 2024

Why Morgan Stanley Likes This Growth Stock for AI Upside in 2025

With the launch of a new feature, analysts believes this company may soon join the S&P 500.

Barchart · Dec 12, 2024

Stocks Settle Lower Ahead of US Inflation News

The S&P 500 Index ($SPX ) (SPY ) Monday closed down -0.61%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.54%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.84%. Stocks on Monday settled lower, with the Dow Jones Industrials posting a 1-1/2 week...

Barchart · Dec 9, 2024

Reddit Stock Gets Boost From Morgan Stanley: Analyst Sees 'Best In Class Growth'

Morgan Stanley upgrades Reddit stock to Overweight with $200 price target, citing potential for explosive growth and $300 bull case.

Benzinga · Dec 9, 2024

Stocks Weaken Ahead of US Nov CPI Report

The S&P 500 Index ($SPX ) (SPY ) today is down -0.45%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.65%. Stocks today are under pressure, with the markets awaiting US inflation news this week...

Barchart · Dec 9, 2024

Demystifying Lululemon Athletica: Insights From 20 Analyst Reviews

Providing a diverse range of perspectives from bullish to bearish, 20 analysts have published ratings on Lululemon Athletica (NASDAQ:LULU) in the last three months.

Benzinga · Dec 9, 2024

Tesla To $370? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga · Dec 9, 2024

Critical Insights From Lazard Analyst Ratings: What You Need To Know

Ratings for Lazard (NYSE:LAZ) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

Benzinga · Dec 9, 2024

A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 19 Analysts

In the last three months, 19 analysts have published ratings on Vertex Pharmaceuticals (NASDAQ:VRTX), offering a diverse range of perspectives from bullish to bearish.

Benzinga · Dec 9, 2024

Analyst Expectations For Moelis's Future

Moelis (NYSE:MC) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

Benzinga · Dec 9, 2024